VIP and endothelin receptor antagonist: an effective combination against experimental pulmonary arterial hypertension. - Wikidata - awgldk - TriplyDB

VIP and endothelin receptor antagonist: an effective combination against experimental pulmonary arterial hypertension.

VIP and endothelin receptor antagonist: an effective combination against experimental pulmonary arterial hypertension.

http://www.wikidata.org/entity/Q35533520

about

Role of endothelin in uteroplacental circulation and fetal vascular function A comprehensive review: the evolution of animal models in pulmonary hypertension research; are we there yet?NFATc3 and VIP in Idiopathic Pulmonary Fibrosis and Chronic Obstructive Pulmonary Disease Vasoactive intestinal peptide attenuates liver ischemia/reperfusion injury in mice via the cyclic adenosine monophosphate-protein kinase a pathway."Denervation" of autonomous nervous system in idiopathic pulmonary arterial hypertension by low-dose radiation: a case report with an unexpected outcome.Novel Targets of Drug Treatment for Pulmonary Hypertension.Macitentan treatment retards the progression of established pulmonary arterial hypertension in an animal model.Augmentation of the effects of vasoactive intestinal peptide aerosol on pulmonary hypertension via coapplication of a neutral endopeptidase 24.11 inhibitor.Pulmonary Hypertension Is a Probable NO/ONOO− Cycle Disease: A Review

P2860

Q26828020-1C222FB3-C417-4690-B586-03A96755A216 Q27026643-9D57CB6A-1B76-46FE-9BDB-D923DF377F64 Q36261127-6FFEA06C-1BB3-4090-99A8-415D652038B8 Q37179294-519EBEBB-5E8E-4690-8488-053C37B2296A Q37678161-9CBD37C8-6A85-4C6E-A8A3-D63C5E4D93A1 Q38504399-A7EC9C58-3716-44A6-ADA0-2A826AD84598 Q41875085-736A2FE5-95E8-4F19-BDA6-4E97AB73AD08 Q53642234-C621477D-8056-411F-AF6C-F2CD39A79AA8 Q58998388-F68D3E00-70C8-4FA4-81BC-DD740908F757

P2860

VIP and endothelin receptor antagonist: an effective combination against experimental pulmonary arterial hypertension.

http://www.wikidata.org/entity/Q35533520

description

2011 nî lūn-bûn

@nan

2011 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

VIP and endothelin receptor an ...... lmonary arterial hypertension.

@ast

VIP and endothelin receptor an ...... lmonary arterial hypertension.

@en

type

label

VIP and endothelin receptor an ...... lmonary arterial hypertension.

@ast

VIP and endothelin receptor an ...... lmonary arterial hypertension.

@en

prefLabel

VIP and endothelin receptor an ...... lmonary arterial hypertension.

@ast

VIP and endothelin receptor an ...... lmonary arterial hypertension.

@en

P1433

Q35533520-F056C2A5-2C5A-4420-B45E-55DC6F86609A

P1476

Q35533520-98791934-65BD-4080-A2DD-1B6D8C5673B3

P2093

Q35533520-0BEF9144-B692-47CB-90A7-B301DB790F87

Q35533520-219F7ADF-423D-4CBA-A6BC-51DEA6438ABD

Q35533520-3ACFB8B1-1119-4AE3-A4C1-6278DB93A858

Q35533520-3C695EFF-B7EB-4BF5-A962-1A83B60CF6FB

Q35533520-C0781230-2DD7-4749-9883-6F54F596811A

Q35533520-FBF28F64-3FE3-4EBE-B368-60B1E962B1B7

P2860

Q35533520-0D9A3944-43EA-4D2E-B1BB-51134C40E78B

Q35533520-1A1B8E02-118A-4D00-A2AD-D7A10778120B

Q35533520-1C190887-1483-4324-BF6B-0906AD0042B4

Q35533520-29DEEE46-9BF7-46B0-BE02-CCBE29270E5B

Q35533520-337F4E16-EC8C-49A1-8405-9E5EB54CE978

Q35533520-47FBF59C-9970-42B0-9D53-F710CEA496EC

Q35533520-57D78240-7679-495B-93A9-2BBC8A64D486

Q35533520-5AE0D34A-DCC8-465B-AA2B-D4553AF536A6

Q35533520-6BBB92BE-B115-4224-99E9-49734DBA87AF

Q35533520-72693758-DB38-4D35-8BAE-1849A64D3130

P2888

Q35533520-16ACDAF1-D722-4538-BA1A-FACBE5E41596

P304

Q35533520-5F67F5D6-D5ED-4932-8358-BF9C5907604F

P31

Q35533520-DAB670D6-7BDA-4EED-A3A5-1511C6348FE1

P356

Q35533520-1261D4B6-D8D3-46AE-975A-128B4E3E0CB2

P478

Q35533520-B91947A6-D56E-4F5E-9712-B2871FEFCF37

P577

Q35533520-363ED282-7D50-408C-9A0E-BC67E86FCB72

P5875

Q35533520-3AB7D986-0428-4E31-9D5F-CA09FE25D9E2

P6179

Q35533520-126ACF20-D202-4096-96C6-A345B8BFECA3

P698

Q35533520-FBE07B97-A770-44D6-B4AE-E5D000EB7E7C

P932

Q35533520-98EA672D-34D3-4CB9-90F5-B9903E5BF2E4

P356

1465-9921-12-141

P1433

Respiratory Research

P1476

VIP and endothelin receptor an ...... lmonary arterial hypertension.

@en

P2093

Anthony M Szema

http://www.w3.org/2001/XMLSchema#string

Richard Z Lin

http://www.w3.org/2001/XMLSchema#string

Sami I Said

http://www.w3.org/2001/XMLSchema#string

Sayyed A Hamidi

http://www.w3.org/2001/XMLSchema#string

Sergey Lyubsky

http://www.w3.org/2001/XMLSchema#string

Ya Ping Jiang

http://www.w3.org/2001/XMLSchema#string

P2860

Management of pulmonary arterial hypertension with a focus on combination therapies.

PDGF signaling in pulmonary arterial hypertension.

Pathways of inflammation and cell death in the lung: modulation by vasoactive intestinal peptide.

Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension

Inflammation in pulmonary arterial hypertension.

Pharmacogenetics and drug development: the path to safer and more effective drugs.

Treatment of pulmonary arterial hypertension.

Mediators and modulators of pulmonary arterial hypertension.

Pulmonary hypertension due to BMPR2 mutation: a new paradigm for tissue remodeling?

Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cure.

P2888

1465-9921-12-141

P304

141

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1465-9921-12-141

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P577

2011-10-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51747751

http://www.w3.org/2001/XMLSchema#string

P6179

1022239909

http://www.w3.org/2001/XMLSchema#string

P698

22029879

http://www.w3.org/2001/XMLSchema#string

P932

3210095

http://www.w3.org/2001/XMLSchema#string